CONCERT PHARMACEUTICALS INC (CNCE) Stock News
NASDAQ:CNCE - Nasdaq - US2060221056 - Common Stock - Currency: USD
CNCE Latest News, Press Relases and Analysis
Concert retains breakthrough tag for hair loss therapy despite rival entry (NASDAQ:CNCE)
Concert Pharmaceuticals (CNCE) announced Wednesday that the FDA allowed it to keep the Breakthrough Therapy Designation for hair loss therapy deuruxolitinib. Read the full story here.
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
India-Based Sun Pharma Scoops Up Concert Pharmaceuticals For $576M Plus Milestones
Sun Pharma entend acquérir Concert Pharmaceuticals pour faire progresser le traitement potentiel de l'alopécie areata
Ajoute à son portefeuille le deuruxolitinib, un inhibiteur oral des Janus kinases qui pourrait être le meilleur de sa catégorie pour le traitement de...
Sun Pharma adquire Concert Pharmaceuticals, avançando no tratamento potencial para a Alopecia Areata
Adiciona o Deuruxolitinib, possível inibidor de JAK Oral para o tratamento da Alopecia Areata, uma doença dermatológica autoimune Aproveita a infraestrutura...
Sun Pharma adquiere Concert Pharmaceuticals para avanzar en el tratamiento de la alopecia areata
Añade deuruxolitinib, un inhibidor oral de JAK potencialmente mejor de su clase para el tratamiento de la alopecia areata, una enfermedad dermatológica...
Sun Pharma erwirbt Concert Pharmaceuticals und treibt damit die Behandlung von Alopecia areata voran
Dadurch wird Deuruxolitinib, ein potenziell klassenbester oraler JAK-Inhibitor zur Behandlung von Alopecia areata, einer autoimmunen dermatologischen...
Why Concert Pharmaceuticals Stock Rocketed Higher This Week
The company is changing hands in a deal worth at least $576 million.
SHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc.
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert...
Hot Stocks: CNCE takeover deal; SRDX plunges; EDU reaches 52-week high; RIVN sets new low
RIVN set a 52-week low. CNCE jumped on a takeover deal. SRDX fell on a regulatory setback. EDU reached a 52-week high.
Shareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun Pharma
/PRNewswire/ -- Ademi LLP is investigating Concert (NASDAQ: CNCE) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun...
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
